menu

The Future of Heart Failure Management: Rethinking Approaches to Care

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

The Future of Heart Failure Management: Rethinking Approaches to Care

5 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.    

    Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ileana L. Piña, MD, MPH, FAHA, FACC

    Clinical Professor of Medicine
    College of Medicine
    Central Michigan University
    Mount Pleasant, MI 
    Consulting Fees: Novartis, Relypsa

    Faculty:
    Javed Butler, MD, MBA, MPH

    Professor & Chair, Department of Medicine
    University of Mississippi Medical Center
    Jackson, MS
    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
    Consultant Cardiologist and Professor of Cardiology
    Cardiovascular Clinical Academic Group
    St. George’s Hospitals NHS Trust University of London
    London, United Kingdom
    No relevant relationships reported

    Marco Metra, MD
    Full Professor of Cardiology
    Director of the Institute of Cardiology
    Civil Hospital and University of Brescia
    Brescia, Italy
    COI

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • James Seternus, DO, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discern current gaps in GDMT for patients with heart failure (HF)
    • Discuss key updates to HFA guidelines for the treatment of HF with focus on optimizing RAASi therapy
    • Evaluate the role of potassium binders in the management of patients with HF experiencing recurrent hyperkalemia
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 30 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    In the management of patients with heart failure, foundational therapy is critical to improving patient outcomes. Are you up to date on the latest recommendations concerning MRAs, ACEI/ARBs/ARNI, beta-blockers, and SGLT2 inhibitors? Recent updates to the ESC/HFA guidelines, heart failure clinical trials, and the COVID-19 pandemic have impacted the way we manage our patients, so tune in to keep up with the latest developments.    

    Our experts, Drs. Ileana Piña, Javed Butler, Marco Metra, and Giuseppe Rosano, discuss the ESC/HFA guideline updates and how these changes impact the clinical considerations for managing recurrent hyperkalemia and the recommended foundational therapy for patients with heart failure.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Ileana L. Piña, MD, MPH, FAHA, FACC

    Clinical Professor of Medicine
    College of Medicine
    Central Michigan University
    Mount Pleasant, MI 
    Consulting Fees: Novartis, Relypsa

    Faculty:
    Javed Butler, MD, MBA, MPH

    Professor & Chair, Department of Medicine
    University of Mississippi Medical Center
    Jackson, MS
    Consulting Fees: Abbott, Adrenomed, Amgen, Array, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CVRx, G3 Pharmaceuticals, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, Novo Nordisk, Relypsa, Roche, V-Wave Ltd., Vifor Pharma

    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
    Consultant Cardiologist and Professor of Cardiology
    Cardiovascular Clinical Academic Group
    St. George’s Hospitals NHS Trust University of London
    London, United Kingdom
    No relevant relationships reported

    Marco Metra, MD
    Full Professor of Cardiology
    Director of the Institute of Cardiology
    Civil Hospital and University of Brescia
    Brescia, Italy
    COI

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Megan Clem has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • William A. Mencia, MD, FACEHP, CHCP, has nothing to disclose.
    • James Seternus, DO, has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Discern current gaps in GDMT for patients with heart failure (HF)
    • Discuss key updates to HFA guidelines for the treatment of HF with focus on optimizing RAASi therapy
    • Evaluate the role of potassium binders in the management of patients with HF experiencing recurrent hyperkalemia
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, nephrologists, primary care physicians, and all other professionals involved in the identification and treatment of HF.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 30 minutes of nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from Vifor Pharma.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule23 Jan 2022
Webpack App